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Although the natural polyphenol resveratrol posses a direct vasorelaxant effect, its effects on cytoplasmic Ca2+ concentration ([Ca2+]i) in vascular
cells remain still unclear. Here, we have investigated the effects of the isomers trans- and cis-resveratrol on agonist- and high-K+-induced [Ca2+]i
increases and on voltage-activated transmembrane Ca2+ fluxes using imaging and patch-clamp techniques in vascular A7r5 myocytes. Arginine
vasopressin (AVP) or angiotensin II caused a biphasic increase in [Ca2+]i that was reduced by preincubation with trans-resveratrol and cis-resveratrol.
Both isomers also reduced the agonist-induced increase in [Ca2+]i in absence of extracellular Ca
2+. In high-K+ Ca2+-free solution, reintroduction of Ca2+
caused a sustained rise in [Ca2+]i that was reduced by preincubation with trans-resveratrol or cis-resveratrol. When the isomers were applied during the
plateau phase of the agonist- or the high-K+-induced response, a biphasic change in [Ca2+]i was observed: a transient reduction of the plateau (b5 min)
followed by an increase (N10 min). Finally, trans-resveratrol and cis-resveratrol inhibited voltage-dependent L-type Ca2+ currents (ICa(L)). In
conclusion, resveratrol isomers exert a dual effect on [Ca2+]i handling inA7r5myocytes: 1) a blockade of ICa(L) and 2) an increase in [Ca
2+]i by depletion
of intracellular Ca2+ stores (which interferes with the agonist-induced release of intracellular Ca2+) and influx of Ca2+, mainly due to activation of
capacitative Ca2+ entry, although other Ca2+-permeable channels are also involved. Taken together, these effects may explain, in part, the endothelium-
independent vasorelaxant effects of resveratrol in rat aorta.
© 2007 Elsevier B.V. All rights reserved.Keywords: A7r5; Calcium; Fura-2; Patch-clamp; Resveratrol1. Introduction
Resveratrol (3,4′,5-trihydroxystilbene), is a polyphenolic
component of a wide variety of plants which is present in grapes
and wines (especially red wines) in significant amounts. Res-
veratrol has been reported to possess a wide range of biological
activities, including anti-inflammatory, anticarcinogenic, antiox-
idant, estrogenic, platelet antiaggregatory, and antimicrobial
properties (for review see, e.g., Soleas et al., 1997; Aggarwal
et al., 2004; Baur and Sinclair, 2006; Orallo, 2006b). Although
resveratrol exists as cis and trans isomers, most studies to date on
the biological effects of resveratrol have considered the trans
isomer (Orallo, 2006a,b), possibly as a result of the fact that this
isomer is the only one available commercially.⁎ Corresponding author. Tel.: +34 981 594488x14895; fax: +34 981 594595.
E-mail address: fforallo@usc.es (F. Orallo).
0014-2999/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejphar.2007.08.003Many studies have also described properties of resveratrol that
could be implicated in the prevention of cardiovascular diseases
(for review see, e.g., Burjonroppa and Fujise, 2006; Campos-
Toimil et al., in press). In rats, trans-resveratrol has been shown to
prevent increase in blood pressure in hypertensive rats (Mizutani
et al., 2000). In vivo protection by trans-resveratrol against
increase in systolic blood pressure, and subsequent cardiac
hypertrophy, has also been reported by Liu et al. (2005a). Despite
the above considerations, the in vitro vasorelaxant activity of
resveratrol is presently somewhat controversial. For example,
trans-resveratrol (at concentrations up to 100 μM), was unable to
relax phenylephrine-precontracted smooth muscle of rat aortic
rings (Fitzpatrick et al., 1993). On the other hand, Chen and Pace-
Asciak (1996) reported that trans-resveratrol (N30 μM) concen-
tration-dependently inhibited the contractile response to nor-
adrenaline or phenylephrine in isolated endothelium-intact rat
aorta. This inhibitory effect was blocked by pretreatment of the
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arginine. These authors also shown that, at higher concentrations
(N60 μM), resveratrol relaxed endothelium-denuded aortic rings,
but this effect could not be reversed by Nω-nitro-L-arginine.
Similarly, we have reported that trans-resveratrol exhibits in
rat aorta: a) a characteristic endothelium-dependent vasorelax-
ant effect (at concentrations b10 μM), probably mediated by an
inhibition of vascular NADH/NADPH oxidase (Orallo et al.,
2002) and b) an endothelium-independent vasodilator effect (at
concentrations N50 μM), which appears to be partially mediated
by an inhibition of protein kinase C (Orallo and Camiña, 1998).
Since vascular tone directly depends on [Ca2+]i levels in smooth
muscle cells, any action of resveratrol on calcium signalling
in these cells may be related to the endothelium-independent
vasorelaxant action of the drug. Surprisingly, in a previous study
we have shown that trans-resveratrol and cis-resveratrol caused a
sustained elevation in [Ca2+]i in single A7r5 cells (a cell line
derived from foetal rat aorta), although the resveratrol-induced
increase in [Ca2+]i seems to be unrelated to rat aorta contractility
(Campos-Toimil et al., 2005). However, from our experiments we
could not discard the possibility of resveratrol acting as an inhibitor
of agonist-induced increases in [Ca2+]i.
The aim of the present study was to further elucidate the
effects of resveratrol isomers on Ca2+ handling in vascular cells
by evaluating, for the first time, their effects on the agonist- and
the high-K+-induced [Ca2+]i changes using a fura-2 based Ca
2+
imaging setup in A7r5 vascular myocytes. Additionally, using
the whole-cell patch-clamp technique we have examined the role
of resveratrol isomers in the activation of voltage-operated Ca2+
entry in these cells. In all the experiments we have compared
trans-resveratrol and cis-resveratrol in order to investigate
whether they have different actions or, on the contrary, the
difference on their effects is merely quantitative.
2. Materials and methods
2.1. Cell culture
A7r5 smooth muscle cells, a well-established vascular
smooth muscle cell line obtained from embryonic rat aorta
(American Type Culture Collection; CRL1446; Rockville, MD,
USA), were grown and kept in culture as described elsewhere
(Campos-Toimil et al., 2005). The culture medium was
Dulbecco's modified Eagle's medium/Ham's F-12 medium
(1:1 v/v) supplemented with heat-inactivated foetal bovine
serum (FBS, 10% v/v), L-glutamine (2 mM), penicillin G
(100 units/ml), streptomycin (100 μg/ml) and amphotericin B
(0.25 μg/ml). Cells kept in culture at 37 °C with 5% CO2 in air.
For imaging experiments, the cells were subcultured at low
density (∼1500 cells/cm2) in 35 mm Petri dishes in which a
20 mm diameter hole had been cut in the base and replaced by a
thin (0.1 mm) glass coverslip. Cells were allowed to grow for at
least 24 h in culture medium and kept in culture for 2–5 days
before the experiments.
For patch-clamp experiments, confluent cells were trypsi-
nized and 50–100 μl of the cell suspension was transferred to a
15 ml plastic tube containing 3–4 ml of FBS-free culturemedium that was kept at 4 °C for 2–5 h until the realization of the
electrophysiological experiments. Then, 5–10 μl of the FBS-
free cell suspension was added to a Petri dish, previously kept at
4 °C with bovine serum albumin (0.2% w/v), containing the
patch-clamp extracellular solution (see below for composition).
2.2. Measurement of [Ca2+]i in isolated vascular smooth
muscle cells
[Ca2+]i imaging experiments were carried out as previously
described (Campos-Toimil et al., 2005). Briefly, A7r5 cells were
incubated for 60 min at 37 °C in normal bathing solution
(composition in mM: NaCl 140, KCl 5, CaCl2·2H2O 1.5,
MgCl2 2, HEPES 10, glucose 11, pH 7.4) containing 2.5 μM
fura-2 acetoxymethyl ester (fura-2 AM), then gently washed
and allowed to rest for N15 min in the incubator. Cells were
placed on an inverted microscope and continuously superfused
at 0.5 ml/min with normal bathing solution except during the
application of drugs. For experiments in extracellular Ca2+-free
medium, CaCl2 was replaced by 10 mM EGTA. Pairs of
fluorescence images at 340±10 nm and 380±10 nm were
obtained every 2–20 s from isolated cells or small groups of
dispersed cells (up to 6 cells). Images were digitally stored and
analyzed using MetaFluor software (Universal Imaging Corpo-
ration, PA, USA).
Drugs (or vehicles, for the corresponding control experi-
ments) were added in volumes of 10 to 50 μl to a final
incubation volume of 2 ml of bathing solution. All procedures
and experiments were performed at room temperature (∼20 °C)
to minimize compartmentalization and cell extrusion of the
fluorescent dye.
2.3. Whole-cell patch-clamp recording
The whole-cell configuration of the patch-clamp technique
(Hamill et al., 1981; Verde et al., 1999) was used to record the
voltage-dependent L-type Ca2+ current (ICa(L)) in A7r5 cells.
The control extracellular solution contained (mM): NaCl 107.1,
CsCl 40.0, CaCl2 1.8, MgCl2 1.8, Na–piruvate 5.0, NaHCO3
4.0, NaH2PO4 0.8, HEPES 10.0, glucose 5.0, pH 7.4 adjusted
with NaOH. Patch pipettes (2–4 MΩ) were filled with
intracellular solution (mM): CsCl 119.8, CaCl2 0.06, MgCl2
4.0, Na–ATP 3.1, Na–GTP 0.4, EGTA 5.0, HEPES 10.0,
tetraethylammonium sodium salt 10.0, pH 7.4 adjusted with
CsOH. K+ currents were blocked by replacing all K+ ions with
intracellular and extracellular Cs+. Solutions were filtered
(0.22 μm) before use.
The cells were maintained at −80 mV holding potential (Vh)
and routinely depolarised every 8s to 0 mV test potential during
500 ms. Currents were not compensated for capacitance and leak
currents. All experiments were carried out at room temperature
(21–25 °C) and the temperature did not vary bymore than 1 °C in
a given experiment. The cells were voltage clamped using an
Axopatch 200B patch-clamp amplifier (Axon Instruments Inc.,
Union City, CA, USA). Currents were sampled at a frequency of
10 kHz and filtered at 0.1 kHz using an analog-to-digital inter-
face Digidata 1322A (Axon Instruments Inc.) connected to a
Fig. 1. (A) Original tracing illustrating the AVP-induced biphasic increase in
[Ca2+]i in a single A7r5 cell. Effects of the preincubation with trans-resveratrol or
cis-resveratrol (20 min) on the increase in [Ca2+]i induced by 0.5 μMAVP (B) or
0.1 μM angiotensin II (C) in A7r5 cells. Each bar represents the mean±S.E.M.
(indicate by vertical lines) of, at least, 15 cells. [Ca2+]i values just before the
addition of AVP or angiotensin II in control and resveratrol-treated cells are
indicated by horizontal lines (see also Table 1). Level of statistical significance:
⁎Pb0.05 and ⁎⁎Pb0.01 with respect to the corresponding control value.
##Pb0.01 with respect to the corresponding [Ca2+]i level before agonist
application.
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ments Inc.). Control or drug-containing solutions were applied to
the exterior by placing the cell at the opening of 250 μm inner
diameter capillary flowing at a rate of 20 μl/min.
2.4. Drugs and chemicals
Angiotensin II, amphotericin B, arginine vasopressin (AVP),
bovine serum albumin, dimethylsulfoxide (DMSO), trans-
resveratrol, L-glutamine, ionomycin, nifedipine, penicillin G,
tetraethylammonium sodium salt and streptomycin were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).
Thapsigargin was from RBI (Natick, MA, U.S.A.). Ryanodine
was from ICN Biochemicals (Asse-Relegem, Belgium). Trypsin/
EDTAwas from Roche Diagnostics (Barcelona, Spain). Dulbec-
co's modified Eagle's medium/Ham's F-12 medium and FBS
were from Gibco-Life Technologies (Grand Island, NY, USA).
Fura-2 AMwas fromMolecular Probes (Eugene, OR, USA). cis-
resveratrol was prepared at the Departamento de Química
Orgánica (Universidade de Santiago de Compostela, Spain)
following the method previously described (Leiro et al., 2004).
All other reagents were of analytical grade.
Stock solutions of these compounds were prepared and
stored at −20 °C as follows: angiotensin II (1 mM), AVP
(1 mM), Ni2+ (10 mM) in deionized water; ionomycin (1 mM),
nifedipine (10 mM), ryanodine (10 mM), thapsigargin (1 mM),
trans-resveratrol (100 mM) and cis-resveratrol (100 mM) in
DMSO. For patch-clamp experiments, stock solutions of
nifedipine (10 mM), trans-resveratrol (100 mM) and cis-
resveratrol (100 mM) were prepared in absolute ethanol. From
these stock solutions, appropriate dilutions in distilled water or
extracellular solution were freshly prepared every day as were
needed for experiments. Final concentration of DMSO and
ethanol never exceeded 0.01% and 0.1% (v/v), respectively.
Fura-2 AM (5 μM) was prepared daily in physiological buffer
containing DMSO (0.1% v/v).
Studies involving light-sensitive compounds (trans-resvera-
trol, cis-resveratrol and nifedipine) were carried out in the dark.
For imaging experiments, appropriate precautionary measures
were taken throughout the procedure to avoid degradation of
light-sensitive compounds and extensive photobleaching due to
the photosensitivity of the fura-2 molecule.
2.5. Data presentation and statistical analysis
Unless otherwise specified, results shown in the text and
figures are expressed as mean±S.E.M. Significant differences
between two means (Pb0.05 or Pb0.01) were determined by
Student's two-tailed t test for paired or unpaired data or by one-
way analysis of variance (ANOVA) followed by Bonferroni's
post-hoc test, where appropriate.
For each cell, [Ca2+]i was averaged from pixels within
manually outlined cell areas. Background compensation was
performed by subtracting the illumination from an area of the
image which contained no cells. The [Ca2+]i was then calculated
from the 340/380 nm fluorescence ratio as described by
Grynkiewicz et al. (1985). For more details see Campos-Toimilet al. (2005). Basal [Ca2+]i was determined by averaging resting
Ca2+ values measured for 10 s on cells from different
preparations. Only data obtained from cells that responded to
Table 2
Ratio peak/plateau for the absolute [Ca2+]i levels induced by AVP (0.5 μM) and
angiotensin II (0.1 μM) in the absence (control) and in the presence of
resveratrol isomers









AVP 4.08 2.39 2.29 1.35 1.17
Angiotensin II 3.00 1.43 1.19 1.16 1.07
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1.5 mM of external CaCl2, at the end of the experiments were
used.
ICa(L) amplitudes were automatically calculated between the
maximum current peak and the stable current plateau near the
final of the pulse. ICa(L) variations were studied in control
extracellular solution containing or not drugs.
3. Results
3.1. AVP- or angiotensin II-induced increases in [Ca2+]i in a
1.5 mM Ca2+-containing medium
In a calcium containing solution, mean basal [Ca2+]i was
80.8±4.4 nM (n=67), and, in absence of any treatment, it was
unchanged throughout the experimental time course.
AVP (0.5μM)caused a biphasic increase in [Ca2+]i (Fig. 1A,B):
first, a transient elevation (peak) in [Ca2+]i within 1–2 min
(maximal [Ca2+]i reached: 685.2±30.9 nM, n=67, Pb0.01 with
respect to basal value) followed by a sustained plateau ([Ca2+]i:
167.7±9.5 nM, n=67, Pb0.01 with respect to basal and peak
values). This plateau was maintained for, at least, 45 min in the
presence of the agonist and returned to basal value after wash. The
plateau phase of the AVP-induced response was partially inhibited
by 1 μM nifedipine ([Ca2+]i: 128.2±8.5 nM, n=18, Pb0.05) and
completely abolished by 300 μM Ni2+ ([Ca2+]i: 80.6±7.2 nM,
n=7, Pb0.01; PN0.05 with respect to basal value).
The application of angiotensin II (0.1 μM) induced a biphasic
increase in [Ca2+]i that was qualitatively similar to that induced
by AVP (Fig. 1C), with a transient peak of 394.5±17.1 nM and
a sustained plateau of 131.3±10.5 nM (n=31, Pb0.01 with
respect to basal value), which was stable for, at least, 45 min in
the continuous presence of the agonist. The plateau phase of the
angiotensin II-induced response was partially inhibited by 1 μM
nifedipine ([Ca2+]i: 99.7 ± 4.2 nM, n=18, Pb0.05) and
completely abolished by 300 μM Ni2+ ([Ca2+]i: 75.3±7.0 nM,
n=10, Pb0.01; PN0.05 with respect to basal value).
3.2. Effects of the preincubation with resveratrol isomers on the
AVP- or angiotensin II-induced increase in [Ca2+]i in a
1.5 mM Ca2+-containing medium
In order to investigate the effects of trans- and cis-resveratrol
(10, 60 μM) on the biphasic increase in [Ca2+]i induced by AVPTable 1
Maximal [Ca2+]i (nM) induced by trans-resveratrol and cis-resveratrol in
1.5 mM Ca2+-containing solution (sustained increase) and in a high-K+ (60 mM)
Ca2+-free solution (transient increase)
1.5 mM Ca2+ High-K+/Ca2+-free
trans-resveratrol 10 μM 190.4±9.9b (41) 101.6±13.1a (12)
60 μM 231.5±9.8b (37) 145.4±13.2b (10)
cis-resveratrol 10 μM 203.1±10.3b (36) 116.9±9.9b (11)
60 μM 263.8±10.5b,c (32) 152.2±15.8b (12)
Level of statistical significance: aPb0.05 or bPb0.01 with respect to basal
values; cPb0.05 with respect to trans-resveratrol. The number of experiments
(n) is given in brackets.or angiotensin II, they were added to the bath 20 min before
application of the agonists and caused a slow sustained elevation
in [Ca2+]i (Table 1). In these conditions, the peak phase of the
increase in [Ca2+]i elicited by the subsequent application of AVP
(0.5 μM) was significantly reduced and the plateau phase was
completely inhibited (Fig. 1B). Similar results were obtained
using angiotensin II (0.1 μM) as agonist (Fig. 1C).
It is important to note here that, considering the absolute [Ca2+]i
values, the agonist-induced [Ca2+]i peak is reduced by resveratrol
isomers, while the plateau is increased, suggesting that the [Ca2+]i
rise induced by resveratrol preincubation is maintained after the
application of AVP or angiotensin II (Fig. 1). To achieve a better
understanding, we have also made a comparison between control
and resveratrol-treated values using the ratio peak/plateau
(considering the absolute [Ca2+]i values), which was reduced in
a concentration-dependent fashion by the isomers and it was lower
for cis-resveratrol than for trans-resveratrol (Table 2).
3.3. Effects of the application of the resveratrol isomers on the
plateau phase of the AVP- or angiotensin II-induced increase
in [Ca2+]i in a 1.5 mM Ca
2+-containing medium
The plateau phase of the AVP- and angiotensin II-induced
rise in [Ca2+]i in A7r5 cells is mainly due to influx of
extracellular Ca2+ (see Discussion). To evaluate the effects of
resveratrol isomers on Ca2+ influx during this phase, they were
added to the bath once the [Ca2+]i plateau was stabilized. When
the isomers of resveratrol (60 μM) were applied during the
plateau phase of the AVP- or angiotensin II-induced response, a
biphasic change in [Ca2+]i was observed: 1) an initial transient
reduction of the agonist-evoked plateau that occurs during the
first 5 min; 2) a sustained increase, starting ∼10 min after the
application of the isomers, that stabilizes ∼15–20 min later in
values similar or higher to those of the previous agonist-induced
plateau (Fig. 2A–C).
Note that, at a concentration of 10 μM, only cis-resveratrol
induced a significant increase of the AVP- or angiotensin II-
induced [Ca2+]i plateau after 20 min of incubation (Fig. 2B,C).
3.4. Effects of the resveratrol isomers on the AVP- or angiotensin
II-induced increase in [Ca2+]i in a Ca
2+-free medium
The agonist-induced [Ca2+]i peak was significantly inhibited
by resveratrol isomers (see above). To evaluate if they inhibit
the release of Ca2+ from intracellular IP3-sensitive Ca
2+ stores,
we have measured their effects on the AVP- and the angiotensin
II-induced increase in [Ca2+]i in Ca
2+-free solution. In these
Fig. 2. (A) Representative recording illustrating the effects of cis-resveratrol
(c-RESV, 60 μM) applied on the plateau phase of the 0.5 μM AVP-induced
increase in [Ca2+]i. Changes on the plateau phase of the increase in [Ca
2+]i
induced by 0.5 μM AVP (B) or 0.1 μM angiotensin II (C) 5 or 20 min after
the application of trans-resveratrol or cis-resveratrol. Each bar represents the
mean±S.E.M. (indicate by vertical lines) of, at least, 14 cells. Level of
statistical significance: ⁎Pb0.05 and ⁎⁎Pb0.01 with respect to control values;
#Pb0.05 and ##Pb0.01 with respect to the [Ca2+]i measured 5 min after the
application of the resveratrol isomers.
Fig. 3. (A) Representative recording illustrating the [Ca2+]i rises induced by
angiotensin II (0.1 μM) in Ca2+-free solution and by the subsequent
reintroduction of 1.5 mM Ca2+-containing external solution. Effects of
resveratrol isomers on the increases in [Ca2+]i induced by AVP (0.5 μM) or
angiotensin II (0.1 μM) in Ca2+-free solution (B) and on the increase in [Ca2+]i
measured after reintroduction of Ca2+ (1.5 mM) in the extracellular solution (C).
Each bar represents the mean±S.E.M. (indicate by vertical lines) of, at least, 10
cells. Level of statistical significance: ⁎Pb0.05 and ⁎⁎Pb0.01 with respect to
control values.
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with respect to the basal value in extracellular 1.5 mM Ca2+-
containing solution). Treatment with AVP (0.5 μM) or
angiotensin II (0.1 μM) induced an increase [Ca2+]i consisting
in a fast peak that returned to basal value in∼5 min (Fig. 3A,B).
After that, substitution of the free-Ca2+ by a 1.5 mM Ca2+
external solution (normal bathing solution) induced an increasein [Ca2+]i (Fig. 3A,C), probably due to Ca
2+ entry through store-
operated Ca2+ channels (Putney, 1990) although, according to
previous data, nifedipine-sensitive Ca2+ channels may also be
implicated (Campos-Toimil et al., 2005).
The addition of resveratrol isomers (10, 60 μM) at the
beginning of the experiment induced a significant transient
increase in [Ca2+]i (Table 3) that returned to basal value after
∼20–25 min. In these conditions, the increase in [Ca2+]i
Table 3
Maximal [Ca2+]i (nM) induced by trans-resveratrol and cis-resveratrol in Ca
2+-free medium before the application of any agonist, after the application of AVP
(0.5 μM) or angiotensin II (0.1 μM) and after several consecutive applications of 0.5 μM AVP (after ≥3 AVP)
trans-resveratrol cis-resveratrol
10 μM 60 μM 10 μM 60 μM
Before agonist 109.7±11.8b (25) 156.6±11.1b (25) 118.8±10.4b (24) 167.5±15.8b (27)
After AVP 70.3±9.8 (12) 120.3±14.2b (12) 73.9±12.1 (12) 132.2±14.1b (14)
After ≥3 AVP 73.6±8.1 (10) 93.3±6.8a (12) 75.3±9.6 (9) 109.4±12.2b (9)
After angiotensin II 80.4±8.8 (10) 138.3±19.2b (12) 79.1±9.0 (11) 156.2±21.9b (10)
Level of statistical significance: aPb0.05 or bPb0.01 with respect to basal values. There were no significant differences between both isomers. The number of
experiments (n) is given in brackets.
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angiotensin II (0.1 μM) was significantly reduced (Fig. 3B).
After the agonist-induced [Ca2+]i rise, trans-resveratrol or
cis-resveratrol (60 μM, but not 10 μM) were still able to
increase [Ca2+]i, which was maximal after 10 min (Table 3).
The elevation in [Ca2+]i measured after reintroduction of
1.5 mM Ca2+ was significantly potentiated in the presence of
resveratrol isomers (60 μM, but not 10 μM) (Fig. 3C).
In order to achieve a complete depletion ofAVP-sensitiveCa2+
intracellular stores, several administrations of this agonist
(0.5 μM) were made in the absence of extracellular Ca2+.
Depending on the cell, the AVP-induced increase in [Ca2+]i was
completely absent after two or three consecutive applications.
This lack of response to AVP was not due to receptor desen-
sitization, since AVP was able to elicit an increase in [Ca2+]i after
reintroducing Ca2+ in the extracellular solution (data not shown).
After depletion of AVP-sensitive Ca2+ stores, trans-resveratrol
and cis-resveratrol (60 μM) or thapsigargin (0.5 μM) were still
able to induce a significant increase in [Ca2+]i (Table 3; maximal
[Ca2+]i reached with thapsigargin: 158.4±22.4 nM, n=10,
Pb0.01 with respect to basal value). On the other hand, trans-
resveratrol and cis-resveratrol (10 μM) were without effect.
3.5. Effects of ryanodine on [Ca2+]i in Ca
2+-free medium
The alkaloid ryanodine has been shown to activate specific
receptors implicated in the mechanism of Ca2+ induced Ca2+
release. However, several authors have questioned the existence
of such mechanism in A7r5 cells (see Discussion). To confirm or
deny this lack of effect of ryanodine, we have evaluated its
effects on [Ca2+]i in Ca
2+-free medium. In these conditions,
ryanodine (0.1–1 μM) did not induce significant changes in
[Ca2+]i ([Ca
2+]i 3 min after application of 1 μM ryanodine:
68.9±8.8 nM, n=18, PN0.05 with respect to basal value). The
subsequent application of trans-resveratrol or cis-resveratrol
(60 μM) provoked an increase in [Ca2+]i not significantly
different from that induced in the absence of ryanodine (data
not shown).
3.6. Effects of the resveratrol isomers on the high-K+-induced
increase in [Ca2+]i
The possibility of an action of resveratrol isomers on voltage-
operated Ca2+ channels contributing significantly to their
relaxant effects in vascular smooth muscle led us to carry outthese experiments, in which cell membranes were depolarized
by using a high-K+ Ca2+-free extracellular solution. The
replacement of 1.5 mM Ca2+-containing extracellular solution
by a depolarizing high-K+ (60mM) Ca2+-free solution induced a
decrease in basal [Ca2+]i levels (66.5±4.2 nM; n=68; Pb0.05
with respect to the value in extracellular 1.5 mM Ca2+-
containing solution) which was maintained for, at least, 2 h.
Reintroduction of Ca2+ (1.5 mM) in the extracellular medium
provoked a sustained increase in [Ca2+]i (maximal [Ca
2+]i
reached: 227.9±22.1 nM; n=16; Pb0.01 with respect to basal
value) (Fig. 4A,B). This responsewas abolished in the continuous
presence of nifedipine (1 μM) (maximal [Ca2+]i: 69.3±8.5 nM;
n=7; PN0.05 with respect to basal value).
The incubation with trans-resveratrol or cis-resveratrol (10,
60 μM) provoked a significant transient increase in [Ca2+]i that
returned to basal value after ∼20-25 min (Table 1). Then,
reintroduction of Ca2+ (1.5 mM) in the extracellular solution, in
the presence of both resveratrol isomers, induced an increase in
[Ca2+]i significantly lower than that provoked in the absence of
the stilbenes (except for 10 μM trans-resveratrol; Fig. 4A,B).
The application of resveratrol isomers (10, 60 μM) during
the [Ca2+]i plateau induced by reintroduction of Ca
2+
significantly reduced this plateau during the first 5 min. Then
[Ca2+]i starts to rise again until reaching values higher to those
of the initial plateau (Fig. 4B,C). Note that the effects of 60 μM
cis-resveratrol are significantly different from those obtained
with the same concentration of trans-resveratrol.
3.7. Inhibition of ICa(L) by the resveratrol isomers
This set of experiments was performed with the purpose of
confirming the inhibition of voltage-operated Ca2+ channels by
resveratrol isomers in A7r5 cells. In whole-cell clamped cells,
trans-resveratrol (10–100 μM) and cis-resveratrol (30–100 μM)
inhibited a voltage-dependent sustained ICa(L) in a concentration-
dependent way, trans-resveratrol being significantly more
effective than the cis isomer. Lower concentrations of both
isomers were without effect (Fig. 5).
4. Discussion
AVP or angiotensin II induced an increase in [Ca2+]i in A7r5
cells that is mediated, as well as in other vascular myocytes, by
activation of specific vasopressin V1 and angiotensin AT2
receptors, respectively (Thibonnier et al., 1991; Griendling
Fig. 4. In high-K+ (60 mM) Ca2+-free depolarizing medium, the reintroduction
of CaCl2 (1.5 mM) caused a sustained increase in [Ca
2+]i in A7r5 cells. (A) This
increase in [Ca2+]i was significantly inhibited by 20 min of preincubation with
trans-resveratrol (60 μM) or cis-resveratrol (10, 60 μM). (B) Original tracing
showing the effects of the application of trans-resveratrol (t-RESV, 60 μM) once
the sustained [Ca2+]i increase was stabilized. (C) [Ca
2+]i values measured 5 or
20 min after the application of trans-resveratrol or cis-resveratrol during the
sustained plateau of this response (C). Each bar represents the mean±S.E.M.
(indicated by vertical lines) of, at least, 11 cells; ⁎Pb0.05 or ⁎⁎Pb0.01 with
respect to control values; †Pb0.01 with respect to trans-resveratrol.
Fig. 5. Inhibition of the ICa(L) by trans-resveratrol and cis-resveratrol measured
in whole-cell patch-clamp experiments in A7r5 cells. Each bar represents the
mean±S.E.M. (indicated by vertical lines) of the number of experiments
indicated between brackets at the top of the bar; ⁎Pb0.05 or ⁎⁎Pb0.01 with
respect to control values with vehicle; #Pb0.05 or ##Pb0.01 with respect to
trans-resveratrol.
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[Ca2+]i, mainly due to the release of Ca
2+ from intracellular
stores, followed by a sustained plateau, mainly due to the influx
of Ca2+ through several types of transmembrane Ca2+-
permeable channels (Thibonnier et al., 1991; Byron and Taylor,
1995; Jung et al., 2002). In vascular myocytes, Ca2+ is released
from intracellular stores via IP3-sensitive (IP3 receptors) and
ryanodine sensitive channels (ryanodine receptors). However,A7r5 cells used here do not have functional ryanodine receptors,
since they did not respond to ryanodine, according to previous
reports (Byron and Taylor, 1993; Missiaen et al., 1994) and
contrary to the results of Berman et al. (1994).
Our results in absence of extracellular Ca2+ confirm that the
peak of the agonist-induced response is mainly due to Ca2+
release from intracellular stores through IP3 receptors, although
this peak is significantly lower than the obtained in a Ca2+-
containing solution, agreeing well with the results reported by
Hughes and Schachter (1994) using the same cell line. The
previous depletion of intracellular stores by agonists signifi-
cantly reduced the increase in [Ca2+]i evoked by resveratrol
isomers. Similarly, after a transitory increase in [Ca2+]i induced
by resveratrol isomers in absence of extracellular Ca2+, the
subsequent increase in [Ca2+]i induced by application of AVP or
angiotensin II was significantly reduced. However, after the
complete depletion of IP3-sensitive stores by consecutive
applications of AVP, resveratrol isomers or thapsigargin were
still able to increase [Ca2+]i.
From these results and taking in account our previous report
(Campos-Toimil et al., 2005), the resveratrol-induced increase
in [Ca2+]i in absence of extracellular Ca
2+ seems to be mediated
by the depletion of Ca2+ from IP3-sensitive intracellular stores.
Additionally, resveratrol isomers may mobilize Ca2+ from a
store that was not depleted by IP3, which corresponds, in part, to
the intracellular pool of Ca2+ depleted by thapsigargin. This fact
supports the hypothesis of trans-resveratrol and cis-resveratrol
interfering with sarcoplasmic/endoplasmic reticulum Ca2+-
ATPase activity in a similar way that thapsigargin, although
further experiments are required to verify this possibility. From
our experiments we cannot discard the possibility of trans-
resveratrol and cis-resveratrol activating a novel Ca2+-induced
Ca2+ release mechanism that is neither mediated by IP3 recep-
tors nor by ryanodine receptors (Kasri et al., 2003), which has
been shown to be stimulated by disulfonated stilbene deriv-
atives (Nadif et al., 2005).
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[Ca2+]i evoked by trans-resveratrol or cis-resveratrol, both
phases of the calcium response to AVP and angiotensin II were
significantly modified, leading to a concentration-dependent
reduction in the peak/plateau ratio calculated for the calcium
response. A possible reason for the reduction of the peak phase
is that the IP3-sensitive stores were partially depleted by
resveratrol isomers, as suggested by the experiments in Ca2+-
free solution (see above).
On the other hand, Ca2+ influx into A7r5 cells induced by
agonists and resveratrol isomers may take place, in part, via
similar mechanisms (an influx of extracellular Ca2+ activated by
depletion of intracellular stores). However, the increase in [Ca2+]i
induced by resveratrol isomers is higher than the AVP- or
angiotensin II-induced plateau in the controls, suggesting that not
all the transmembrane Ca2+ channels activated by the agonist or
the resveratrol isomers are precisely the same. In fact, the influx
of Ca2+ induced by resveratrol isomers may be also mediated by
Ca2+-permeable channels that are not affected by Ni2+ (Campos-
Toimil et al., 2005) while, in the present work, sustained agonist-
induced Ca2+ influx was completely blocked by Ni2+, in
accordance with a previous report (Hughes and Schachter, 1994).
From our results in depolarizing high-K+ Ca2+-free solution, it
seems that the increase in [Ca2+]i provoked by the reintroduction
of extracellular Ca2+ is mainly mediated through ICa(L). Although
it has been shown that Ca2+ influx through ICa(L) may activate
calcium-induced Ca2+ release in several preparations, including
guinea pig aorta or rat portal vein (Ito et al., 1991; Ganitkevich
and Isenberg, 1992), this is not the case forA7r5 cells in this study,
since they lack of this mechanism, which is also activated by
ryanodine (see above). In high-K+ Ca2+-free solution, incubation
with trans-resveratrol or cis-resveratrol induced an increase
in [Ca2+]i which is not significantly different to that obtained in
Ca2+-free solution. Although it could be expected that resveratrol
isomers will potentiate Ca2+ entry through ICa(L) because of the
additional capacitative Ca2+ influx after depletion of Ca2+ stores,
the fact is that the increase in [Ca2+]i after reintroduction of
1.5 mM Ca2+ was significantly reduced. This suggests that both
stilbenes may act directly blocking Ca2+ entry through ICa(L), a
hypothesis also supported by our patch-clamp results. In good
agreement, other authors have recently shown that trans-
resveratrol may inhibit Ca2+ currents through ICa(L) in rat
ventricular myocytes (Liu et al., 2005b; Zhang et al., 2006;
Chen et al., 2007). Furthermore diethylstilbestrol, a synthetic
estrogen structurally related to resveratrol, have been shown to
inhibit ICa(L) in A7r5 cells (Nakajima et al., 1995).
Interestingly, resveratrol isomers displayed a biphasic effect
when they were applied on a AVP-, angiotensin II- or high-K+-
induced stable [Ca2+]i plateau. A possible explanation for the
initial 5 min inhibitory effect is the above described inhibition of
ICa(L) since: i) nifedipine also partially inhibited the plateau
phase of the calcium response induced by the agonists; ii) this
inhibitory effect was stronger on the high-K+-induced plateau
compared to the agonist-induced plateau; and iii) the % of
inhibition of ICa(L) for each concentration of trans-resveratrol or
cis-resveratrol correlates well with their ability to reduce the
[Ca2+]i plateau. On the other hand, at least three mechanismscould explain why [Ca2+]i starts to rise again after N5 min: i)
resveratrol isomers may exert a dual effect on some of the Ca2+
channels participating in the plateau phase, an inverse situation
to that provoked by (−)-epigallocatechin-3-gallate on ICa(L)
(Campos-Toimil and Orallo, 2007); ii) an additional depletion
of intracellular [Ca2+]i followed by the subsequent potentiation
of extracellular Ca2+ influx; and iii) the later activation of a type
of channel that was not participating in the initial Ca2+ response:
in this respect, it is interesting to note that the calcium response
to resveratrol isomers occurs in two different phases: the first one
(5–10min) corresponding to the release of intracellular Ca2+ and
store activated Ca2+ influx and the second one (15–20min) takes
place through a non-identified type of channels (Campos-Toimil
et al., 2005; unpublished observations). A similar effect
(simultaneous activation and blockade of different Ca2+
channels) has been previously described for other natural
compounds, as the alkaloid rutaecarpine (Wang et al., 1999).
Throughout this study there were no qualitative differences
between the effects of resveratrol isomers, in good agreement
with most comparative studies on the biological effects of cis-
resveratrol vs. trans-resveratrol (Campos-Toimil et al., 2005;
Orallo, 2006a), suggesting that the different conformation does
not modify markedly its interaction with the potential cellular
targets involved in Ca2+ signalling in A7r5 cells.
To summarize, both resveratrol isomers exert two differ-
ent actions on the Ca2+ signalling in A7r5 myocytes: i) a
concentration-dependent inhibition of ICa(L) and ii) a slow increase
in [Ca2+]i by depletion of IP3-sensitive and IP3-non-sensitive
intracellular Ca2+ stores, that is potentiated by the activation of
store-operated Ca2+ entry, although the later activation of another
transmembraneCa2+-permeable channel may be also involved.As
a result of these actions, resveratrol isomers reduce agonist- and
high-K+-induced increases in [Ca2+]i and exert a biphasic effect
when applied on the sustained plateau. The overall effects of
resveratrol isomers described here may explain, at least in part, the
endothelium-independent vasorelaxant effects exhibited by resver-
atrol isomers in isolated rat aortic rings (see Introduction), thus
contributing to the cardioprotective effects induced by the long-
term moderate wine consumption (Orallo et al., 2002). Bearing in
mind these pharmacological properties and assuming that
resveratrol isomers exhibit similar behaviour in humans in vivo,
it can be concluded that they may have interesting potential as an
original chemical model for the design and subsequent develop-
ment of new drugs with cardioprotective properties.
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